All funds

Franklin Biotechnology Discovery Fund A(acc)USD

Equity fund

1 year

Region

USA

Largest region

High

Risk

Cost

Morningstar

 

Partial 

Sustainability

Development

Last 5 years
( ann.)

Description

  • Fondet investerer hovedsakelig i aksjeverdipapirer utstedt av bioteknologiselskaper av enhver størrelse , og som befinner seg i USA og i andre land Fondet kan investere i mindre omfang i gjeldsobligasjoner av høyere kvalitet utstedt av selskaper Et bioteknologiselskap er et selskap som har minst 50 % av sitt overskudd fra eller er involvert i virksomheter som forskning, utvikling, produksjon og distribusjon av ulike bioteknologiske eller biomedisinske produkter, tjenester og prosesser. Fondet vil normalt investere mer i USA enn i noe annet land.
    Read more

Investment horizon

  • Franklin Biotechnology Discovery Fund A(acc)USD is a Equity fund. This mutual fund type is suitable for those who plan to save for at least 6 years.

Characteristics

  • Minimum amount
  • Sharpe 3 years
  • Price/NAV

    05 Jun 2025

  • Start date
    02 Apr 2000
  • ISIN
    LU0109394709

Risk

  • High (5 of 7)

Morningstar rating

  • The Morningstar Rating is an objective standard that tells us how well a fund has done compared to similar funds. If a fund performs better than other funds it is compared with, it receives a high rating. Correspondingly, a fund receives a low rating if it performs worse than similar funds.

Sustainability

Costs

  • Ongoing costs

    Includes management fees of 1,50 %

  • Platform fee
  • Kickback fee
  • Annual running costs
  • Performance-based fee

  • Any transaction costs to the manager are not included in the cost overview. These are stated under cost details on the summary page before you purchase the fund. Costs for any currency exchanges are not included.

Allocation

  • Stocks 95%
    Interest 5%

Portfolio

Shows the fund's largest investments.

  • Vertex Pharmaceuticals Inc
    7.9%
  • Gilead Sciences Inc
    7.5%
  • Amgen Inc
    7.3%
  • Regeneron Pharmaceuticals Inc
    5.0%
  • Ascendis Pharma AS ADR
    4.7%
  • argenx SE ADR
    4.1%
  • Jazz Pharmaceuticals PLC
    3.8%
  • Merus NV
    3.1%
  • PTC Therapeutics Inc
    2.9%
  • Eli Lilly and Co
    2.5%